Skip to main content
SpringerLink
Log in

The Role of Bisphosphonates in the Treatment of Skeletal Complications of Breast Cancer

  • Review Article
  • Published:
American Journal of Cancer

Abstract

Bone metastasis from breast cancer can result in significant morbidity including hypercalcemia, fractures, spinal cord compression, and pain. Treatment modalities have included radiation therapy, surgery, analgesia, and bisphosphonates.

Clodronic acid, pamidronic acid, ibandronic acid, and zoledronic acid are the four bisphosphonates that have been investigated in metastatic breast cancer. Pamidronic acid, clodronic acid, and ibandronic acid, evaluated in this setting in randomized, double-blind, placebo-controlled trials, have all demonstrated significant improvements in delaying and treating skeletal events in breast cancer patients, including symptom improvement. Pamidronic acid and zoledronic acid appear to be equal with respect to efficacy and safety.

Based on several large randomized studies, pamidronate 90mg infused over 2 hours, or zoledronic acid 4mg over 15 minutes every 3–4 weeks is recommended in patients with breast cancer and radiographic evidence of bone destruction. The major toxicity associated with either bisphosphonate is renal impairment and, therefore, monitoring of serum creatinine levels prior to each administration of either agent is recommended. The adverse effects of this class of agents also include gastrointestinal symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III

Similar content being viewed by others

References

  1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61–6

    Article  PubMed  CAS  Google Scholar 

  2. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588–94

    Article  PubMed  CAS  Google Scholar 

  3. Coleman RE. Uses and abuses of bisphosphonates. Ann Oncol 2000; 11: 179–84

    PubMed  Google Scholar 

  4. Chlebowski RT. Factors influencing the role of bisphosphonates in breast cancer management. Semin Oncol 2001; 28: 42–8

    Article  PubMed  CAS  Google Scholar 

  5. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999; 6: 333–47

    Article  PubMed  CAS  Google Scholar 

  6. Pluijm G, Lowik C, Papapoulos S. Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. Cancer Treat Rev 2000; 26: 11–27

    Article  PubMed  CAS  Google Scholar 

  7. Flelsch H. Experimental basis for the use of bisphosphonates in Paget’s disease of bone. Clin Orthop 1987; 217: 72–8

    Google Scholar 

  8. Flelsch H. Bisphosphonates: history and experimental basis. Bone 1987; 8: S23–8

    Article  Google Scholar 

  9. Smith MR. Bisphosphonates. Philadelphia (PA): Lippincott Williams and Wilkins, 2001: 700–706

    Google Scholar 

  10. Flelsch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80–100

    Article  Google Scholar 

  11. Singer FR, Minoofar PN. Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab 1995; 6: 259–88

    PubMed  CAS  Google Scholar 

  12. Body JJ. Bisphosphonates. Eur J Cancer 1998; 34: 263–9

    Article  PubMed  CAS  Google Scholar 

  13. Lowik CW, van der Pluijm G, van der Wee-Pals LJ, et al. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res 1988; 3: 185–92

    Article  PubMed  CAS  Google Scholar 

  14. Hughes DE, MacDonald BR, Russcil RG, et al. Inhibition of osteoclast-like cell formation by bisphosphonates in long- term cultures of human bone marrow. J Clin Invest 1989; 83: 1930–5

    Article  PubMed  CAS  Google Scholar 

  15. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095–105

    Article  PubMed  CAS  Google Scholar 

  16. Zimolo Z, Wesolowski G, Rodan GA. Acid extrusion is induced by osteoclast attachment to bone: Inhibition by alendronate and calcitonin. J Clin Invest 1995; 96: 2277–83

    Article  PubMed  CAS  Google Scholar 

  17. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478–87

    Article  PubMed  CAS  Google Scholar 

  18. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding protelns, including Ras. J Bone Miner Res 1998, 13: 581–9

    Article  PubMed  CAS  Google Scholar 

  19. Nishikawa M, Akatsu T, Katayama Y, et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996; 18: 9–14

    Article  PubMed  CAS  Google Scholar 

  20. Sahni M, Guenther HL, Flelsch H, et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 91: 2004–11

    Article  PubMed  CAS  Google Scholar 

  21. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15: 2211–21

    Article  PubMed  CAS  Google Scholar 

  22. van der Pluijm G, Vloedgraven H, van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698–705

    Article  PubMed  Google Scholar 

  23. Magnetto S, Boissier S, Delmas PD, et al. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999; 83: 263–9

    Article  PubMed  CAS  Google Scholar 

  24. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126–34

    Article  PubMed  CAS  Google Scholar 

  25. Coleman RE, Rubens RD. Bone metastases and breast cancer. Cancer Treat Rev 1985; 12: 251–70

    Article  PubMed  CAS  Google Scholar 

  26. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785–91

    Article  PubMed  CAS  Google Scholar 

  27. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial: Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846–54

    PubMed  CAS  Google Scholar 

  28. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate: Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038–44

    PubMed  CAS  Google Scholar 

  29. Conte PF, Giannessi PG, Latrellle J, et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Ann Oncol 1994; 5: S41–4

    Article  PubMed  Google Scholar 

  30. Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59–65

    PubMed  CAS  Google Scholar 

  31. Kristensen B, Ejlertsen B, Groenvold M, et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999; 246: 67–74

    Article  PubMed  CAS  Google Scholar 

  32. Ernst DS, Brasher P, Hagen N, et al. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997; 13: 319–26

    Article  PubMed  CAS  Google Scholar 

  33. Diel IJ, Marschner N, Kindler M, et al. Continual oral versus intravenous therapy with bisphosphonates in patients with breast cancer and bone metastasis. Atlanta (GA): ASCO, 1999

    Google Scholar 

  34. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19: 558–67

    PubMed  CAS  Google Scholar 

  35. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191–200

    Article  PubMed  CAS  Google Scholar 

  36. Rosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377–87

    PubMed  CAS  Google Scholar 

  37. Body JJ, Lichinitser M, Diehl I, et al. Double blinded placebo control trial of intravenous ibandronate in breast cancer metastatic to bone. Atlanta (GA): ASCO, 1999: 2222

    Google Scholar 

  38. Tripathy D, Lazarev A, Lichinister MR, et al. Oral ibandronate lowers the incidence of skeletal complications in breast cancer patients with bone metastasis. Orlando (FL): ASCO, 2002

    Google Scholar 

  39. Coleman RE, Purohit OP, Black C, et al. Double-blind, randomised, placebocontrolled dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999; 10: 311–6

    Article  PubMed  CAS  Google Scholar 

  40. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulos-clerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164–72

    PubMed  CAS  Google Scholar 

  41. Tyrrell CT, Bruning PF, May-Levin F, et al. Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer. Eur J Cancer 1995; 31A: 1976–80

    Article  PubMed  CAS  Google Scholar 

  42. Van Pozanak CH, Ben-Porat L, Panageas K, et al. Renal safety of 1 hour infusion rate of pamidronate in patients with metastatic breast cancer. Orlando (FL), 2002

  43. Vilimovskij A, Thuerlimann JR, Berenson JR, et al. Renal safety and tolerability of 90mg of Aredia administered as an intravenous 1 hour infusion: preliminary results. Atlanta (GA): ASCO, 1999: 2223

    Google Scholar 

  44. Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19: 3434–7

    PubMed  CAS  Google Scholar 

  45. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000; 18: 1378–91

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA

    Basil F. El-Rayes &  Patricia M. LoRusso

  2. Wayne State University, Harper Hospital, 4100 John R, HWCRC 4th Floor, Detroit, MI, 48201, USA

    Patricia M. LoRusso

Authors
  1. Basil F. El-Rayes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia M. LoRusso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patricia M. LoRusso.

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-Rayes, B.F., LoRusso, P.M. The Role of Bisphosphonates in the Treatment of Skeletal Complications of Breast Cancer. Am J Cancer 3, 369–375 (2004). https://doi.org/10.2165/00024669-200403060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200403060-00004

Keywords

Search

Navigation